Date: 2012-08-08
Type of information: Initiation of the trial
phase: 1-2
Announcement: initiation of the trial
Company: Eli Lilly (USA - IN)
Product: ralimetinib (LY2228820)
Action
mechanism: MAP-kinase inhibitor. Ralimetinib is a P38 mitogen-activated protein kinase inhibitor.
Disease: ovarian cancer
Therapeutic area: Cancer - Oncology
Country: Australia, Belgium, Germany, India, USA
Trial
details: The study is a randomized, double-blind, placebo-controlled phase 1b/2 study of LY2228820, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with platinum-sensitive ovarian cancer that has returned at least 6 months after platinum-based chemotherapy. (NCT01663857)
Latest
news: * On August 8, 2012, a Phase 2 trial sponsored by Eli Lilly was published on the NIH website ClinicalTrials.gov ralimetinib (LY2228820) and is currently recruiting participants.
